[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-risk-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-risk-bleeding":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100639327",false,"NCT07602257","Investigating a Personalized Approach to Anti-Platelet Therapy","Reassessment of Anti-Platelet Therapy Using an Individualized Strategy With Pharmacogenomics to Refine Anti-Platelet Drugs in Vulnerable Patients to Eliminate Thrombotic and Bleeding Complications - A Cluster Randomized Pilot Study","RAPID PREVENT","Inclusion Criteria:\n\n* Age \\>18 years old\n* Receiving PCI with stenting\n\nExclusion Criteria:\n\n* Inability to take ticagrelor\n* Inability to take clopidogrel\n* Not expected to survive \\>48hours\n* Not able to complete a buccal swab","ALL","18 Years",{"count":19,"type":20},1760,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","RAPID PREVENT aims to identify if a personalized (targeted) anti-platelet strategy will reduce bleeding events when compared to the current standard anti-platelet therapy.",[26],"High Risk Bleeding",[28,29,30],"Thrombosis","bleeding complications","Anti-platelet therapy","NOT_YET_RECRUITING","2026-05-15",{"date":34,"type":35},"2026-05-22","ACTUAL",{"date":37,"type":20},"2026-06-01",{"date":39,"type":20},"2029-12-28",{"name":41,"class":42},"Ottawa Heart Institute Research Corporation","OTHER",""]